Krystal Biotech, Inc. (KRYS)

Environment story

Krystal Biotech is a biotech company with limited disclosed environmental data. No Scope 1, 2, or 3 emissions figures are disclosed in the 10-K filing. The company operates two CGMP manufacturing facilities (one original, one called ASTRA opened in 2023) but provides no public environmental targets, renewable energy commitments, or net-zero goals. No evidence of carbon-reduction initiatives, sustainability reporting, or environmental controversies is present in the document. The company's therapeutics are gene therapies with minimal inherent environmental footprint (non-invasive topical or inhaled delivery), but manufacturing operations' environmental impact remains unquantified and unmanaged. Absence of disclosure on environmental metrics and targets results in significant score penalty.

Social story

Krystal Biotech reports 295 full-time employees as of February 2026 with no unionization and claims good employee relations. The 10-K states none of the employees are represented by a labor union. CEO-to-worker pay ratio is not disclosed. The company emphasizes robust compensation packages, stock-based awards, and training programs. No documented labor disputes, strikes, or NLRB complaints appear in the filing. Diversity metrics for executive/board leadership and workforce (gender, race, ethnicity) are not disclosed in the 10-K. No supply-chain labor audits or human-rights assessments related to manufacturing inputs are mentioned. The company manufactures gene therapies in-house at two facilities but does not disclose supply-chain labor practices or audits. Absence of diversity disclosure and lack of supply-chain ethics transparency result in moderate penalties.

Governance story

Krystal Biotech provides minimal governance disclosure in the 10-K. Board independence percentage is not disclosed. Share structure (single vs. dual-class) is not explicitly described, though no mention of founder supermajority voting or preferential shares appears. Lobbying expenditure is not disclosed. The company has not disclosed involvement in major antitrust, consumer-safety, or financial-fraud proceedings. The 10-K references litigation settlement with PeriphaGen ($37.5M in 2024, $12.5M in 2023), but this appears to be intellectual-property related rather than governance misconduct. No evidence of SEC consent decrees, privacy fines, or antitrust actions is present. No shareholder activism proposals or governance controversies are mentioned. Overall governance information is sparse, limiting ability to assess board structure, lobbying risk, or regulatory sanctions.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Krystal Biotech, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Krystal Biotech, Inc. in the app for interactive charts and portfolio building.

More in Healthcare